A Phase I, Randomized, Partially Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers (PDF112166)
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2015
At a glance
- Drugs Lanopepden (Primary)
- Indications Bacterial infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 27 Jan 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 11 Apr 2014 Planned initiation date changed from 1 Nov 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.
- 04 Apr 2014 Planned End Date changed from 1 Aug 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.